Cerebrolysin 60mg

Cerebrolysin is a multi-peptide brain-derived neurotrophic preparation consisting of enzymatically treated porcine brain protein. The preparation contains a mixture of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier. It has been used clinically in Europe, China, and Russia for neurological conditions including stroke, traumatic brain injury, and vascular dementia, with an unusually long clinical history for a peptide complex -- marketed since the 1970s. Each vial contains 60mg of the lyophilized preparation.

The active components of Cerebrolysin are not fully defined chemically, which distinguishes it from single-compound neurotrophic peptides. The preparation has demonstrated neurotrophic factor-like activity in cell culture and animal models: it promotes neuronal survival, enhances synaptic plasticity, stimulates neurogenesis, and exhibits neuroprotective effects in various injury models. Several small clinical trials have shown improvements in stroke recovery and cognitive parameters in Alzheimer's patients, though larger Phase III trials have had more variable results. The European Medicines Agency has approved it for some neurological indications.

For research purposes, Cerebrolysin is a useful tool for studying multi-factor neurotrophic support -- where the combined effect of multiple small peptides may recapitulate some of the biological activity of endogenous neurotrophic factors (BDNF, NGF, GDNF) more completely than any single defined compound.

Specifications

Storage

Store at 2-8°C (refrigerator) as lyophilized powder. Refrigerate after reconstitution and use within 14 days. As a biological preparation, avoid freezing and thawing cycles.

Cerebrolysin is supplied for laboratory research use only. Not approved for general human use outside of licensed therapeutic indications. Handle in compliance with institutional biosafety guidelines.